Michael T. Hemann

Michael T. Hemann

Associate Professor of Biology; Intramural Faculty, Koch Institute

Michael T. Hemann uses mouse models to combat cancers resistant to chemotherapy.

617-324-1964

Phone

76-361

Office

Ryan Hayman

Assistant

617-253-0796

Assistant Phone

Education

  • PhD, 2001, Johns Hopkins University
  • BS, 1993, Molecular Biology and Biochemistry, Wesleyan University

Research Summary

Many human cancers do not respond to chemotherapy, and often times those that initially respond eventually acquire drug resistance. Our lab uses high-throughput screening technology — combined with murine stem reconstitution and tumor transplantation systems — to investigate the genetic basis for this resistance. Our goal is to identify novel cancer drug targets, as well as strategies for tailoring existing cancer therapies to target the vulnerabilities associated with specific malignancies.

Key Publications

  1. Integrated regulatory models for inference of subtype-specific susceptibilities in glioblastoma. Liu, Y, Shi, N, Regev, A, He, S, Hemann, MT. 2020. Mol Syst Biol 16, e9506.
    doi: 10.15252/msb.20209506PMID:32974985
  2. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Dalin, S, Sullivan, MR, Lau, AN, Grauman-Boss, B, Mueller, HS, Kreidl, E, Fenoglio, S, Luengo, A, Lees, JA, Vander Heiden, MG et al.. 2019. Cancer Res 79, 5723-5733.
    doi: 10.1158/0008-5472.CAN-19-0960PMID:31484670
  3. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Bruno, PM, Liu, Y, Park, GY, Murai, J, Koch, CE, Eisen, TJ, Pritchard, JR, Pommier, Y, Lippard, SJ, Hemann, MT et al.. 2017. Nat Med 23, 461-471.
    doi: 10.1038/nm.4291PMID:28263311
  4. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Zhao, B, Sedlak, JC, Srinivas, R, Creixell, P, Pritchard, JR, Tidor, B, Lauffenburger, DA, Hemann, MT. 2016. Cell 165, 234-246.
    doi: 10.1016/j.cell.2016.01.045PMID:26924578
  5. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Pallasch, CP, Leskov, I, Braun, CJ, Vorholt, D, Drake, A, Soto-Feliciano, YM, Bent, EH, Schwamb, J, Iliopoulou, B, Kutsch, N et al.. 2014. Cell 156, 590-602.
    doi: 10.1016/j.cell.2013.12.041PMID:24485462

Recent Publications

  1. Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse. Dalin, S, Grauman-Boss, B, Lauffenburger, DA, Hemann, MT. 2022. Sci Rep 12, 5453.
    doi: 10.1038/s41598-022-09319-1PMID:35361803
  2. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Bent, EH, Millán-Barea, LR, Zhuang, I, Goulet, DR, Fröse, J, Hemann, MT. 2021. Nat Commun 12, 6218.
    doi: 10.1038/s41467-021-26407-4PMID:34711820
  3. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Vassel, FM, Bian, K, Walker, GC, Hemann, MT. 2020. Proc Natl Acad Sci U S A 117, 28922-28924.
    doi: 10.1073/pnas.2016067117PMID:33144509
  4. Integrated regulatory models for inference of subtype-specific susceptibilities in glioblastoma. Liu, Y, Shi, N, Regev, A, He, S, Hemann, MT. 2020. Mol Syst Biol 16, e9506.
    doi: 10.15252/msb.20209506PMID:32974985
  5. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Dalin, S, Sullivan, MR, Lau, AN, Grauman-Boss, B, Mueller, HS, Kreidl, E, Fenoglio, S, Luengo, A, Lees, JA, Vander Heiden, MG et al.. 2019. Cancer Res 79, 5723-5733.
    doi: 10.1158/0008-5472.CAN-19-0960PMID:31484670
  6. Functional screens identify coordinators of RNA molecule birth, life, and death as targetable cancer vulnerabilities. Braun, CJ, Hemann, MT. 2019. Curr Opin Genet Dev 54, 105-109.
    doi: 10.1016/j.gde.2019.04.003PMID:31121413
  7. In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL. Fiedler, ERC, Bhutkar, A, Lawler, E, Besada, R, Hemann, MT. 2018. Blood Adv 2, 1229-1242.
    doi: 10.1182/bloodadvances.2017015610PMID:29853524
  8. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. Ramos, A, Hemann, MT. 2017. Cell 170, 411-413.
    doi: 10.1016/j.cell.2017.07.018PMID:28753421
  9. PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Soto-Feliciano, YM, Bartlebaugh, JME, Liu, Y, Sánchez-Rivera, FJ, Bhutkar, A, Weintraub, AS, Buenrostro, JD, Cheng, CS, Regev, A, Jacks, TE et al.. 2017. Genes Dev 31, 973-989.
    doi: 10.1101/gad.295857.117PMID:28607179
  10. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Bruno, PM, Liu, Y, Park, GY, Murai, J, Koch, CE, Eisen, TJ, Pritchard, JR, Pommier, Y, Lippard, SJ, Hemann, MT et al.. 2017. Nat Med 23, 461-471.
    doi: 10.1038/nm.4291PMID:28263311
More Publications

Multimedia

Photo credit: Bryce Vickmark